A 35-year-old is seeking advice on hair loss treatments, considering minoxidil, finasteride, and possibly a hair transplant in Turkey. They have previously tried microneedling for a year.
CRISPR Cas9 could potentially treat baldness by targeting specific genes in hair follicles without affecting other body functions. There is optimism about its future use, despite ethical concerns and the current reliance on treatments like minoxidil and finasteride.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hair follicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.
The user reported positive hair regrowth after 5 months using Minoxidil, red light therapy, and lifestyle changes, including dietary improvements and stress reduction. They chose natural supplements like saw palmetto and beta-sitosterol over pharmaceutical DHT inhibitors like finasteride.
Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.
Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.
The conversation discusses the potential cost of hair transplants if verteporfin allows for an unlimited donor area, suggesting that prices could vary based on the number of grafts needed. The user speculates that costs could be calculated per graft or a set amount for a specific number of grafts.
The conversation discusses improvements to a platform and mentions hair loss treatments including Minoxidil, finasteride, RU58841, and melatonin. It also highlights the addition of features like Google login, reply by email, keyword extraction, and a term glossary for better understanding of hair-related terminologies.
The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.
A user experienced increased estradiol, nipple tenderness, and ED after taking finasteride. They are considering dose reduction to mitigate these effects.
The conversation discusses verteporfin as a potential hair loss treatment and questions why more precise methods aren't used to test its effectiveness in regrowing hair. Some users believe verteporfin is promising and should receive more attention, while others are skeptical about the testing methods.
The user, InternationalTutor92, shared their progress pictures after using a combination of finasteride, minoxidil, keto shampoo, and dermarolling for a year. They mentioned that their hairline on the left side has improved, and they did not experience any side effects from the treatments.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
This conversation discusses the advancements in treatments for hair loss, including finasteride, dutasteride, minoxidil and new promising treatments such as pyrilutamide and verteporfin. Other treatments discussed were taking minoxidil orally, tretinoin to turn non-responders into responders and microneedling to further boost growth.
User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
The conversation is about using valproic acid, an anti-seizure medication, as a topical treatment to promote hair growth. The original poster is seeking personal experiences from those who have tried this method.
Treatments for hair loss, including microneedling (dermarolling and dermapen) and the use of minoxidil, finasteride, and RU58841. It provides detailed information about cost and usage of the various treatments, as well as potential side effects.
Microneedling can be effective for hair regrowth, especially when used with oils like castor, emu, and rosemary, but should be done with caution regarding needle size and frequency. Some users avoid minoxidil due to its side effects and cost, opting for alternatives like rosemary oil.
PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.
Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.
PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.
PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.